Navigation Links
GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum

NEW YORK, Sept. 9 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), today released important information about its anti-cancer drug development strategy and its unique niche in the drug development industry.

The Company is aggressively acquiring patents involving the latest generation of biotherapeutic technologies that can cure cancer without any side effects.

With a focus on prostate and breast cancers, GENova has acquired a unique class of drugs that utilize stem cell technology to identify, target, and destroy the very originator stem cells that give rise to cancers. These bio-engineered drugs can seek out cancers right at the source, and destroy them whilst leaving healthy tissues intact.

The Company has already filed patents for these drug targets, and has identified similar ones for acquisition. Researchers in academic labs have expressed confidence that this novel approach to treating cancer is the way of the future, and will render current painful treatments obsolete.

John Savin, VP for GENova, explained the Company's unique strategy for penetrating the lucrative drug development industry: "We occupy a strategic point in the drug development and supply chain, as the intermediary between research institutions and the Big Pharmaceutical companies. Our strategy is one of global outsourcing, international collaboration, using the FDA fast track to accelerate drug development, and then early exit to cash-rich and technology-hungry Big Pharma."

Savin said that if GENova's current IP is developed successfully, he estimates that the Company could expect up to $100 Million in milestone payments during clinical trials, and up to $400 Million per annum in the years following commercialization. His estimates are based on evaluations of other successful drug targets in the industry.

Big Pharma presently has $215 Billion to spend on licensing of new drugs, and is eager to feed the pipeline for new anti-cancer drugs, as cancer represents the largest disease market, and has an explosive growth rate of 20% per annum. Of the types of cancer, prostate cancer represents the largest market and breast cancer the second.

Savin expressed confidence that GENova's proprietary IP drug targets for breast and prostate cancer have blockbuster potential in this growing and important industry.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
2. Genova files patent for new prostate cancer treatment
3. GENova names Dr. John Savin as Vice President
4. GENova names Aaron Whiteman as CEO
5. Karmanos Chief Cancer Surveillance Researcher Discusses Study on Decreased Cancer Mortality Rates
6. Lumension Sponsored Webinar Discusses Ways to Protect Patient Data and Comply with HIPAA Security Mandates
7. The Caryl Ehrlich Program Discusses Food Addiction on
8. Natural Healers Discusses How Personal Trainer Certification May Be Changing in Some States
9. Natural Healers Discusses How Alternative Medicine Careers Provide a Little 'Wellness' in a Tough Economy
10. Cord Blood America CEO Discusses New State-of-the-Art State Laboratory in Fox News Television Interview
11. All Nursing Schools Discusses Obama's Health Care Reform and Nursing Career Opportunities
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: